Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) — North America Leads Today, Asia Pacific to Record Fastest Growth
The global high throughput screening market, valued at US$25.7 billion in 2023, stood at US$28.8 billion in 2024 and is projected to advance at a resilient CAGR of 11.8% from 2024 to 2029, culminating in a forecasted valuation of US$50.2 billion by the end of the period. This growth is propelled by surging R&D investments in drug discovery, strategic government funding, and the increasing adoption of automation in life sciences research.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950
What Is Driving the Market Now?
HTS adoption is accelerating due to innovations in automation, miniaturization, and high-content screening, which significantly reduce discovery timelines and enhance precision in identifying therapeutic candidates. Grants such as the USD 7.8 million awarded to the University of Pittsburgh for advanced drug discovery systems underscore growing institutional and government commitment to high-impact research.
Why Does This Matter for Global Pharma and Biotech Leaders?
The market represents a critical enabler for competitive advantage in lead discovery, target validation, compound profiling, and hit identification—processes essential for pipeline acceleration. While high instrument costs remain a barrier, particularly for automated liquid handling and high-resolution imaging systems, emerging markets such as China and India offer lucrative opportunities with strong government support and an expanding pharmaceutical manufacturing base.
Who Are the Key Stakeholders?
The HTS ecosystem spans pharmaceutical giants, biotechnology innovators, academic institutions, and technology providers, all collaborating to enhance assay development and manage the rising complexity …